It’s no lie the drug development model is in need of a drastic shakeup. With lengthy and costly approval processes, generic incursion, rising development costs and the need for novel adherence strategies, pharma and biotech, now more than ever need to initiate innovative formulation, delivery and development approaches in order to improve bioavailability and therapeutic performance.
Small and large molecule therapeutics urgently need to overcome drug formulation and delivery challenges in order to improve bioavailability and therapeutic performance. Because a majority of the drugs in development are hydrophobic (estimated at more than 40%), they need to be modified using chemical, physical, and biological methods to improve the aqueous solubility, and hence, BA. Optimization of drug solubility and BA of therapeutics stands as one of the top challenges faced by the pharmaceutical and biotech industry today.
Optimal bioavailability is important for high efficacy, but bioavailability can be poor in oral drugs. Some successful strategies for improving oral bioavailability of drugs include developing amorphous solid dispersions, nanoparticulates and self-emulsifying drying systems.
This week’s available deck is titled “Trends in Drug Bioavailability Enhancements and its Impact on Portfolio Strategy” from Linda Lohr at Pfizer. Linda was a previous speaker at our Global Drug Bioavailability Enhancement Summit. This presentation overviews discusses formularies, regulatory hurdles lead to focus on first in class across the industry, market drivers influence portfolio strategy, early clinical development: efficient de-risking and proof-of-mechanism / early signs of efficacy studies: concept and benefits. It additionally discusses focus on proof-of-mechanism (PoM) and early signs of efficacy (ESoE) studies increases success in delivering transformational medicines and determining the bioperformance & opportunities for modified release and conducting microdosing PK studies pre POC.
Are you looking to improve the performance of your drug products? Would you like to learn new strategies to improve stability, reduce dosage, increase efficacy and bioavailability, reduce cost, whilst decreasing time-to-market and improving patient compliance?
Join the drug development industry’s leading drug development specialists this March at the 2021 Global Drug Bioavailability Enhancement Summit in San Diego (March 3-4, 2021). Hear from 30+ senior drug bioavailability pioneers and network with 120+ senior drug development innovators and walk away with over 2 years of new drug formulation and bioavailability enhancement approaches strategies in just 2 days!
- 30+ industry-led speaker faculty over 2 full days sharing innovative drug development take-home strategies
- 12+ hours of networking sessions and breaks over two full days to learn from network with pharmaceutical and biotech senior formulation, development and delivery professionals
- 120+ senior participants spanning pharma, biotech and specialty delivery & technology companies
- Dynamic Tech Showcase Hall with multiple leading manufacturing, formulation development, delivery and modeling experts
Additionally, join over 1350 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox